Generic drugs

Home/Tag: Generic drugs

FDA Approves Record Number of Generic Drugs, But Do They Help Lower Drug Prices?

The Food and Drug Administration (FDA) has approved a record number of generic drugs to go to market during President Donald Trump’s tenure, but drug pricing experts say it isn’t doing much to lower drug prices for consumers overall. In an interview with Fox Business, Secretary of Health and Human Services Alex Azar said flooding the

The Other U.S. Prescription Drug Problem

Last week, drugmaker Novartis issued a recall of generic versions of the popular heartburn medication Zantac. The Food and Drug Administration recently announced that the drug's active ingredient, ranitidine, had been contaminated with a carcinogen known as NDMA. On Monday, CVS pulled Zantac and its generics from its shelves; Walgreens had already stopped selling the drug earlier. This

Elements of green chemistry

The chemical sciences has a sustainability problem. Chemical production is expected to double by 2030, according to a recent UN report, but quite how this will be done without costing the Earth is still an unanswered question. At the recent International Union of Pure and Applied Chemistry’s congress in Paris, the ‘father of green chemistry’

2019-08-19T08:33:37-06:00Tags: |

Puerto Rico pharma chiefs: Investors prefer quality, sustainability

Puerto Rico should stop giving so much importance to the island’s tax advantages to attract investors and instead focus more on sustainability and quality at a time when the supply chain factor also increases in importance. That is the consensus of industry experts who attended the Puerto Rico Manufacturers Association Convention over the weekend. Newly

2019-08-02T07:19:54-06:00Tags: |

How can the pharma industry turn its sustainability ambitions into action?

The last few weeks have reiterated the critical importance of sustainability action. From Extinction Rebellion and the overwhelmingly positive response the Committee on Climate Change’s call for net zero emission targets by 2050, to the UN’s report on biodiversity, to the pharma-specific crisis around opioids and prosecutions in the US; the issues are high profile,

2019-07-22T06:53:04-06:00Tags: |

Prescription for Poverty

New Oxfam research shows that four pharmaceutical corporations—Abbott, Johnson & Johnson, Merck & CO (MSD), and Pfizer—systematically stash their profits in overseas tax havens. They appear to deprive developing countries of more than $100 million every year—money that is urgently needed to meet the health needs of people in these countries—while vastly overcharging for their

2019-06-16T14:52:07-06:00Tags: |

How Some Generic Drugs Could Do More Harm Than Good

For the 16 years that Dr. Brian Westerberg, a Canadian surgeon, worked volunteer missions at the Mulago National Referral Hospital in Kampala, Uganda, scarcity was the norm. The patients usually exceeded the 1,500 allotted beds. Running water was once cut off when the debt-ridden hospital was unable to pay its bills. On some of his

Foul play with generic drugs threatens American lives

This is becoming the year of the health care “hot potato,” as various players in the market battle over who is the villain. The Senate Finance Committee kicked off 2019 with hearings aimed at getting to the root of soaring prescription drug prices and identifying bad actors. Suggested solutions ranged from banning price spreading to reforming rebate programs. Yet

A single-dose antidote may help prevent fentanyl overdoses

Synthetic opioids outlast current antidotes. A nanoparticle-based alternative could fix that. A newly developed single-dose opioid antidote lasts several days, a study in mice shows. If the results can be duplicated in humans, the treatment may one day help prevent overdoses from deadly drugs like fentanyl. Normally, a dose of the opioid antidote naloxone passes

2019-04-04T08:19:50-06:00Tags: |

How antibiotics change human microbiome diversity long-term

A single course of antibiotics can change the composition of oral and gut microbiomes for at least a year, according to a modelling study by UCL researchers. Moreover, this change leads to a decrease in the number and types of microbes found in the gut, but an increase in the diversity of the oral microbiome.

2019-03-26T07:50:36-06:00Tags: |

Pharmaceutical abuse sent more than 350,000 people to the ER in 2016

The misuse of prescription drugs and over-the-counter medications resulted in an estimated 358,000 trips to U.S. emergency departments in 2016 — and almost half of those cases involved young people ages 15 to 34, according to a new study based on a national public health surveillance system. The analysis, reported online March 6 in the

2019-03-18T10:58:33-06:00Tags: |

Do price spikes on some generic drugs indicate problems in the market?

A new USC study reports that sudden price spikes for some generic drugs — such as the recently reported increases of a decades-old generic heart medication and an antibiotic — are becoming more common. The study from the USC Schaeffer Center for Health Policy & Economics, published in the October issue of Health Affairs, shows

2019-03-07T07:48:35-06:00Tags: |

Pharmacists can substitute branded drugs with generics

The Prime Minister's office has asked the Drug Technical Advisory Board (DTAB) to move amendments to the Drugs & Cosmetics Act, 1945 that will allow pharmacists to substitute doctor's prescription of branded drugs with generic medicines. Following suggestions, the Drug Controller General of India confirmed that in the initial phase, only the Jan Aushadhi Kendras

2019-03-07T07:40:41-06:00Tags: |

Towards a sustainable system of drug development

Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main

2019-02-27T07:09:19-06:00Tags: |

The Little-Known Way Pharma Companies Hook People On Their Costly Drugs

Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price. “Nothing in the world gives me

2018-12-13T07:48:27-06:00Tags: |

Epicenter of fake pharma

One consequence of African poverty is that quality medication is often unavailable. Health-care systems tend to be weak, and the marketing of pharmaceuticals is not regulated effectively. Many patients depend on sub-standard or even counterfeit drugs. In this setting, a powerful opioid has become easily available – addiction is spreading in West Africa. Tramadol is

2018-12-13T07:41:21-06:00Tags: |

The New Nonprofit Pharmaceutical World: What’s Up with That?

Two new nonprofit pharmaceutical companies, Civica Rx and Harm Reduction Therapeutics, have declared they want to help patients see more money in their pockets by manufacturing low-cost generic drugs. With public trust in for-profit pharmas at an all-time low, especially when it comes to their relationships with a special brand of self-serving philanthropy, they’d better

2018-09-13T07:49:36-06:00Tags: |

8,000 new antibiotic combinations are surprisingly effective

Scientists have traditionally believed that combining more than two drugs to fight harmful bacteria would yield diminishing returns. The prevailing theory is that that the incremental benefits of combining three or more drugs would be too small to matter, or that the interactions among the drugs would cause their benefits to cancel one another out.

2018-09-05T07:15:22-06:00Tags: |

Working group may vet plan to check fake drugs

NEW DELHI: India’s central drug regulator is creating a working group to critically appraise its proposal to set up a “trace and track” mechanism to weed out fake medicines from the market using unique codes. The working group, comprising pharmaceutical association representatives and members of the Central Drugs Standard Control Organisation, is to submit its

2018-08-21T08:28:29-06:00Tags: |